Fannie Mae, Freddie Mac shares tumble after conservatorship comments
In a challenging year for bioAffinity Technologies, the company’s stock has plummeted to a 52-week low, trading at just $0.25. According to InvestingPro data, the stock’s RSI indicates oversold conditions, while its beta of 3.14 reflects significant volatility. This significant downturn reflects a staggering 1-year change, with the stock value eroding by -87.89%. Investors have watched with concern as the company struggled to maintain its market position amidst a tough economic landscape, leading to this new low point. With a market capitalization of just $4.08 million and rapid cash burn, the company faces significant challenges. However, analysts forecast 278% revenue growth for the current year. The current price level serves as a stark indicator of the hurdles bioAffinity Technologies has faced over the past year, marking a period of intense volatility and investor caution within the biotech sector. InvestingPro subscribers can access 12 additional key insights about the company’s financial health and future prospects.
In other recent news, bioAffinity Technologies, Inc. reported a notable 270% increase in revenue for the year ended December 31, 2024, reaching $9.4 million, compared to $2.5 million the previous year. This surge is primarily attributed to the increased demand for its CyPath® Lung test, which is now reimbursed by Medicare and private insurers, following its inclusion in the Centers for Medicare and Medicaid Services’ clinical laboratory fee schedule. Despite the revenue growth, the company anticipates a reduction in total revenue for 2025 due to the discontinuation of certain unprofitable services. In a strategic move, bioAffinity has announced cost-saving measures at its subsidiary, Precision Pathology Laboratory Services, aiming for $4 million in annual savings to focus on CyPath® Lung sales. The company also secured a patent in Australia for its lung cancer test, enhancing its intellectual property portfolio. Meanwhile, bioAffinity Technologies faces a potential Nasdaq delisting due to its stock not meeting the minimum bid price requirement, though it has been granted a 180-day period to regain compliance. Additionally, the company’s CEO, Maria Zannes, received a salary increase, reflecting bioAffinity’s recognition of leadership contributions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.